Retrospective analysis of the DiRECT trial.

LungART trial resolves long-standing controversy of PORT vs no PORT in resected NSCLC.

The identified markers might explain the high susceptibility of older individuals to severe COVID-19 and inform efforts to prevent and treat the disease.

In 40 per cent of cases, the incorrect rate would have led to errors in the early warning score.

Effects of Novo Nordisk’s insulin icodec were similar to once-daily glargine U100.

Higher success rate, fewer arterial punctures or other complications.

Survival and functional status still lagged those of patients with out-of-hospital onset.

Randomized trial finds use of the clock shortens times to imaging and start of thrombolysis.

Older age, SSRI/opioid use, and history of alcohol abuse are significant risk factors.

Survey-based study shows 25%-32% reduction in mortality with various levels of exercise.

Icodec reported HbA1C reductions similar to insulin glargine.

It can take more than 5 years for a diagnosis to be made.

Recent drug safety update.

Talc and petroleum jelly among the best lubricants to protect skin against friction from face masks.